As in previously published studies on patients on MET therapy [23], [24], [44], our findings after NASH treatment noted a significant decrease in liver aminotransferases (ALT, AST, and GGT) after six months of combination therapy. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.